1
|
Nadia J, Wang Y, Li G, Sun L, Mmadi SA, Abdallah KS, Abdallah AM, Shu L, Bacar A, Deng C, Huang X, Zhou X, Song J, Lu F. KNOWLEDGE, ATTITUDES, AND PRACTICES TOWARD MALARIA AND ANTIMALARIAL MASS DRUG ADMINISTRATION AMONG HEADS OF HOUSEHOLDS IN VILLAGES ON GRANDE COMORE ISLAND, THE COMOROS. J Parasitol 2023; 109:187-199. [PMID: 37270766 DOI: 10.1645/22-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Knowledge, attitudes, and practices (KAP) surveys on malaria and antimalarial mass drug administration (MDA) have not received much attention in the Union of the Comoros. This study is a household-based cross-sectional survey using a multi-stage sampling technique aiming at investigating KAP toward malaria and antimalarial MDA with artemisinin-piperaquine among heads of households on Grande Comore Island, the largest island of the Comoros. A predefined structured questionnaire containing socio-demographic characteristics and questions about malaria and antimalarial MDA was administered to 1,368 randomly selected heads of households from 10 malaria-endemic villages on Grande Comore Island. The results showed that 81.4% of the heads of households knew that malaria is a transmissible disease, 77.6% recognized mosquitoes as the vectors of malaria, and 70.8% recognized fever as one of the frequent symptoms of malaria; 40.8% of respondents remembered the name of the antimalarial drug used for MDA, and 62.1% remembered the color of the antimalarial tablets; and 65.1% chose to go to a public health center to seek treatment as their first option within 24 hr of the onset of initial malaria symptoms. This study found that most heads of households had a reasonable level of knowledge about malaria and antimalarial MDA. However, only 7.3% obtained full points on all knowledge-related questions. Misconceptions about malaria cause, transmission, diagnostic method, and antimalarial MDA exist in the community of Grande Comore Island. As the Comoros continues to put great efforts to go toward malaria elimination, the community's KAP on malaria and antimalarial MDA is crucial to guarantee the community's long-term adherence to malaria elimination interventions and could become key to guaranteeing malarial elimination in the Comoros. Therefore, there is a great need to improve malaria prevention awareness through strengthening malaria education and promoting behavioral change. Heads of households should be the core target of malaria education and behavioral change for malaria elimination.
Collapse
Affiliation(s)
- Julie Nadia
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Yuxin Wang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Guoming Li
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Liwei Sun
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Salim Abdoulkarim Mmadi
- Ministry of Health, Social Cohesion, Solidarity, and Gender Promotion, Bâtiment de la Fonction Publique, BP 1028, Moroni, the Union of the Comoros
| | - Kamal Said Abdallah
- National Malaria Control Program, Route de la Corniche, BP 5212, Moroni, the Union of the Comoros
| | - Ali Maoulida Abdallah
- Ministry of Health, Social Cohesion, Solidarity, and Gender Promotion, Bâtiment de la Fonction Publique, BP 1028, Moroni, the Union of the Comoros
| | - Lei Shu
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Affane Bacar
- National Malaria Control Program, Route de la Corniche, BP 5212, Moroni, the Union of the Comoros
| | - Changsheng Deng
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
| | - Xinan Huang
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
| | - Xian Zhou
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou 510440, China
| | - Jianping Song
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
- First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
| | - Fangli Lu
- Clinical Laboratory, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China; Department of Parasitology, School of Medicine, Sun Yat-sen University, Shenzhen 518107, China; Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China; and Key Laboratory of Tropical Disease of the Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China
| |
Collapse
|
2
|
Deng C, Wu W, Yuan Y, Li G, Zhang H, Zheng S, Li M, Tan R, Wang Y, Nadia J, Feng D, Li D, Wu Z, Xu Q, Li C, Wang Z, Liang Y, Doehl JSP, Su X, Bacar A, Said Abdallah K, Mohamed H, Msa Mliva A, Wellems TE, Song J. Malaria Control by Mass Drug Administration With Artemisinin Plus Piperaquine on Grande Comore Island, Union of Comoros. Open Forum Infect Dis 2023; 10:ofad076. [PMID: 36910690 PMCID: PMC10003749 DOI: 10.1093/ofid/ofad076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 02/09/2023] [Indexed: 02/16/2023] Open
Abstract
Background Mass drug administration (MDA) is a powerful tool for malaria control, but the medicines to use, dosing, number of rounds, and potential selection of drug resistance remain open questions. Methods Two monthly rounds of artemisinin-piperaquine (AP), each comprising 2 daily doses, were administered across the 7 districts of Grande Comore Island. In 3 districts, low-dose primaquine (PMQLD) was also given on the first day of each monthly round. Plasmodium falciparum malaria rates, mortality, parasitemias, adverse events, and genetic markers of potential drug resistance were evaluated. Results Average population coverages of 80%-82% were achieved with AP in 4 districts (registered population 258 986) and AP + PMQLD in 3 districts (83 696). The effectiveness of MDA was 96.27% (95% confidence interval [CI], 95.27%-97.06%; P < .00001) in the 4 AP districts and 97.46% (95% CI, 94.54%-98.82%; P < .00001) in the 3 AP + PMQLD districts. In comparative statistical modeling, the effectiveness of the 2 monthly rounds on Grande Comore Island was nearly as high as that of 3 monthly rounds of AP or AP + PMQLD in our earlier study on Anjouan Island. Surveys of pre-MDA and post-MDA samples showed no significant changes in PfK13 polymorphism rates, and no PfCRT mutations previously linked to piperaquine resistance in Southeast Asia were identified. Conclusions MDA with 2 monthly rounds of 2 daily doses of AP was highly effective on Grande Comore Island. The feasibility and lower expense of this 2-month versus 3-month regimen of AP may offer advantages for MDA programs in appropriate settings.
Collapse
Affiliation(s)
- Changsheng Deng
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Wanting Wu
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Yueming Yuan
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Guoming Li
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Hongying Zhang
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Shaoqin Zheng
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Mingqiang Li
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Ruixiang Tan
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Yuxin Wang
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Julie Nadia
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Danhong Feng
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Di Li
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Zhibing Wu
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Qin Xu
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.,First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Changqing Li
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.,First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Zhenhua Wang
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Yuan Liang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Johannes S P Doehl
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Xinzhuan Su
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Affane Bacar
- National Malaria Center of The Union of Comoros, Moroni, The Union of Comoros
| | - Kamal Said Abdallah
- National Malaria Center of The Union of Comoros, Moroni, The Union of Comoros
| | - Hafidhou Mohamed
- National Malaria Center of The Union of Comoros, Moroni, The Union of Comoros
| | - Ahamada Msa Mliva
- National Malaria Center of The Union of Comoros, Moroni, The Union of Comoros
| | - Thomas E Wellems
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - Jianping Song
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.,First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| |
Collapse
|
3
|
Li G, Yuan Y, Zheng S, Lu C, Li M, Tan R, Zhang H, Silai R, Liu R, Said K, Bacar A, Xu Q, Song J, Wu W, Deng C. Artemisinin-Piperaquine versus Artemether-Lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore Island: an open-label, non-randomized controlled trial. Int J Antimicrob Agents 2022; 60:106658. [PMID: 35988664 DOI: 10.1016/j.ijantimicag.2022.106658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 06/28/2022] [Accepted: 08/11/2022] [Indexed: 11/05/2022]
Abstract
BACKGROUND . Malaria has rebounded significantly in 2018 in the Comoros. It posed an urgent need to conduct clinical trials to investigate the effectiveness of artemisinin and its derivatives there. METHODS . From June 2019 and January 2020, an open-label, non-randomized controlled trial of artemisinin-piperaquine (AP) and artemether-lumefantrine (AL) were conducted in Grande Comore Island. 238 uncomplicated falciparum malaria cases were enrolled and divided 1:1 into two treatments. The primary endpoint was the 42-day adequate clinical and parasitological responses (ACPR). Parasitemia and fever clearance at day 3, gametocyte, and tolerability were secondary endpoints. RESULTS . The 42-day ACPR before and after PCR-corrected were 91.43% [95% confidence interval (CI): 83.93%-95.76%] and 98.06% [95%CI: 92.48%-99.66%] for AP treatment, respectively, and 96.00% [95%CI: 88.17%-98.14%] and 98.97% [95%CI: 93.58%-99.95%] for AL treatment, respectively. Complete clearance of the parasitemia as well as of fever for both groups was detected on day 3. Gametocytes disappeared on day 21 in the AP group and on day 2 in AL group, respectively. Specifically, the adverse reactions were mild in both groups. CONCLUSIONS We discovered that AP and AL maintained their high efficacy and tolerance in the Comoros. Nonetheless, asymptomatic malaria infections bring new challenges to malaria control.
Collapse
Affiliation(s)
- Guoming Li
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China
| | - Yueming Yuan
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; Institution of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Shaoqin Zheng
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; Institution of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Chenguang Lu
- Zhang Zhongjing School of Chinese Medicine, Nanyang Institute of Technology, Nanyang, People's Republic of China
| | - Mingqiang Li
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China
| | - Ruixiang Tan
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China
| | - Hongying Zhang
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China
| | - Rahamatou Silai
- National Malaria Center of the Union of Comoros, Moroni, Grande Comore, The Union of Comoros
| | - Ruimei Liu
- Institution of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Kamal Said
- National Malaria Center of the Union of Comoros, Moroni, Grande Comore, The Union of Comoros
| | - Affane Bacar
- National Malaria Center of the Union of Comoros, Moroni, Grande Comore, The Union of Comoros
| | - Qin Xu
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Jianping Song
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China
| | - Wanting Wu
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
| | - Changsheng Deng
- Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
| |
Collapse
|
4
|
Kormos A, Lanzaro GC, Bier E, Dimopoulos G, Marshall JM, Pinto J, Aguiar dos Santos A, Bacar A, Sousa Pontes Sacramento Rompão H, James AA. Application of the Relationship-Based Model to Engagement for Field Trials of Genetically Engineered Malaria Vectors. Am J Trop Med Hyg 2021; 104:805-811. [PMID: 33350374 PMCID: PMC7941841 DOI: 10.4269/ajtmh.20-0868] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 11/10/2020] [Indexed: 12/25/2022] Open
Abstract
The transition of new technologies for public health from laboratory to field is accompanied by a broadening scope of engagement challenges. Recent developments of vector control strategies involving genetically engineered mosquitoes with gene drives to assist in the eradication of malaria have drawn significant attention. Notably, questions have arisen surrounding community and regulatory engagement activities and of the need for examples of models or frameworks that can be applied to guide engagement. A relationship-based model (RBM) provides a framework that places stakeholders and community members at the center of decision-making processes, rather than as recipients of predetermined strategies, methods, and definitions. Successful RBM application in the transformation of healthcare delivery has demonstrated the importance of open dialogue and relationship development in establishing an environment where individuals are actively engaged in decision-making processes regarding their health. Although guidelines and recommendations for engagement for gene drives have recently been described, we argue here that communities and stakeholders should lead the planning, development, and implementation phases of engagement. The RBM provides a new approach to the development of ethical, transparent, and effective engagement strategies for malaria control programs.
Collapse
Affiliation(s)
- Ana Kormos
- Vector Genetics Laboratory, University of California, Davis, California;,Address correspondence to Ana Kormos, Department of Pathology, Microbiology and Immunology, University of California, Davis, 1089 Veterinary Medicine Dr., Davis, CA 95616. E-mail:
| | | | - Ethan Bier
- Section of Cell and Developmental Biology, University of California, San Diego, California;,Tata Institute for Genetics and Society (TIGS)-UCSD, San Diego, California
| | - George Dimopoulos
- Department of Molecular Microbiology and Immunology, Malaria Research Institute (JHMRI), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
| | - John M. Marshall
- Division of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, California;,Innovative Genomics Institute, Berkeley, California
| | - João Pinto
- Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal
| | | | - Affane Bacar
- Ministry of Health, Programme Nationale de Lutte Contre le Paludisme, Moroni, Union of the Comoros
| | | | - Anthony A. James
- Department of Microbiology and Molecular Genetics, University of California, Irvine, California;,Department of Molecular Biology and Biochemistry, University of California, Irvine, California
| |
Collapse
|
5
|
Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, Li D, Feng D, Li G, Xue L, Yang T, Tuo F, Mohadji F, Su XZ, Xu Q, Wu Z, Lin L, Zhou J, Yan H, Bacar A, Said Abdallah K, Kéké RA, Msa Mliva A, Mohamed M, Wang X, Huang S, Oithik F, Li XB, Lu F, Fay MP, Liu XH, Wellems TE, Song J. Large-scale Artemisinin-Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa. Clin Infect Dis 2019; 67:1670-1676. [PMID: 29846536 DOI: 10.1093/cid/ciy364] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 04/23/2018] [Indexed: 01/08/2023] Open
Abstract
Background Mass drug administration (MDA), with or without low-dose primaquine (PMQLD), is being considered for malaria elimination programs. The potential of PMQLD to block malaria transmission by mosquitoes must be balanced against liabilities of its use. Methods Artemisinin-piperaquine (AP), with or without PMQLD, was administered in 3 monthly rounds across Anjouan Island, Union of Comoros. Plasmodium falciparum malaria rates, mortality, parasitemias, adverse events, and PfK13 Kelch-propeller gene polymorphisms were evaluated. Results Coverage of 85 to 93% of the Anjouan population was achieved with AP plus PMQLD (AP+PMQLD) in 2 districts (population 97164) and with AP alone in 5 districts (224471). Between the months of April-September in both 2012 and 2013, average monthly malaria hospital rates per 100000 people fell from 310.8 to 2.06 in the AP+PMQLD population (ratio 2.06/310.8 = 0.66%; 95% CI: 0.02%, 3.62%; P = .00007) and from 412.1 to 2.60 in the AP population (ratio 0.63%; 95% CI: 0.11%, 1.93%; P < .00001). Effectiveness of AP+PMQLD was 0.9908 (95% CI: 0.9053, 0.9991), while effectiveness of AP alone was 0.9913 (95% CI: 0.9657, 0.9978). Both regimens were well tolerated, without severe adverse events. Analysis of 52 malaria samples after MDA showed no evidence for selection of PfK13 Kelch-propeller mutations. Conclusions Steep reductions of malaria cases were achieved by 3 monthly rounds of either AP+PMQLD or AP alone, suggesting potential for highly successful MDA without PMQLD in epidemiological settings such as those on Anjouan. A major challenge is to sustain and expand the public health benefits of malaria reductions by MDA.
Collapse
Affiliation(s)
| | - Bo Huang
- Institute of Tropical Medicine, People's Republic of China
| | - Qi Wang
- Institute of Tropical Medicine, People's Republic of China.,Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Wanting Wu
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Shaoqin Zheng
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Hongying Zhang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Di Li
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Danghong Feng
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Guoming Li
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Linlu Xue
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Tao Yang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Fei Tuo
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Fouad Mohadji
- Ministry of Health Comoros, Moroni, Union of Comoros, Bethesda, Maryland
| | - Xin-Zhuan Su
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Qin Xu
- Institute of Tropical Medicine, People's Republic of China
| | - Zhibing Wu
- First Affiliated Hospital, People's Republic of China
| | - Li Lin
- First Affiliated Hospital, People's Republic of China
| | - Jiuyao Zhou
- Traditional Chinese Medicine College, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Hong Yan
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Affane Bacar
- National Malaria Control Programme, Moroni, Union of Comoros, People's Republic of China
| | - Kamal Said Abdallah
- National Malaria Control Programme, Moroni, Union of Comoros, People's Republic of China
| | - Rachadi A Kéké
- National Malaria Control Programme, Moroni, Union of Comoros, People's Republic of China
| | - Ahamada Msa Mliva
- Ministry of Health Comoros, Moroni, Union of Comoros, Bethesda, Maryland
| | - Moussa Mohamed
- Ministry of Health Comoros, Moroni, Union of Comoros, Bethesda, Maryland
| | - Xinhua Wang
- Guangzhou Medical University, People's Republic of China
| | - Shiguang Huang
- School of Stomatology, Jinan University, People's Republic of China
| | - Fatihou Oithik
- Ministry of Health Comoros, Moroni, Union of Comoros, Bethesda, Maryland
| | - Xiao-Bo Li
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Fangli Lu
- Department of Parasitology, Zhongshan School of Medicine, People's Republic of China.,Key Laboratory of Tropical Disease Control in Ministry of Education, Sun Yat-sen University, Guangdong, People's Republic of China
| | - Michael P Fay
- Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland
| | - Xiao-Hong Liu
- First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| | - Thomas E Wellems
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Jianping Song
- Institute of Tropical Medicine, People's Republic of China.,Science and Technology Park, Guangzhou University of Chinese Medicine, Guangdong, People's Republic of China
| |
Collapse
|
6
|
Huang B, Tuo F, Liang Y, Wu W, Wu G, Huang S, Zhong Q, Su XZ, Zhang H, Li M, Bacar A, Abdallah KS, Mliva AMSA, Wang Q, Yang Z, Zheng S, Xu Q, Song J, Deng C. Temporal changes in genetic diversity of msp-1, msp-2, and msp-3 in Plasmodium falciparum isolates from Grande Comore Island after introduction of ACT. Malar J 2018; 17:83. [PMID: 29458365 PMCID: PMC5819244 DOI: 10.1186/s12936-018-2227-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 02/08/2018] [Indexed: 11/26/2022] Open
Abstract
Background Malaria is still one of the serious public health problems in Grande Comore Island, although the number of annual cases has been greatly reduced in recent years. A better understanding of malaria parasite population diversity and transmission dynamics is critical for assessing the effectiveness of malaria control measures. The objective of this study is to investigate temporal changes in genetic diversity of Plasmodium falciparum populations and multiplicity of infection (MOI) in Grande Comore 10 years after introduction of ACT. Methods A total of 232 P. falciparum clinical isolates were collected from the Grande Comore Island during two sampling periods (118 for 2006‒2007 group, and 114 for 2013‒2016 group). Parasite isolates were characterized for genetic diversity and complexity of infection by genotyping polymorphic regions in merozoite surface protein gene 1 (msp-1), msp-2, and msp-3 using nested PCR and DNA sequencing. Results Three msp-1 alleles (K1, MAD20, and RO33), two msp-2 alleles (FC27 and 3D7), and two msp-3 alleles (K1 and 3D7) were detected in parasites of both sampling periods. The RO33 allele of msp-1 (84.8%), 3D7 allele of msp-2 (90.8%), and K1 allele of msp-3 (66.7%) were the predominant allelic types in isolates from 2006–2007 group. In contrast, the RO33 allele of msp-1 (63.4%), FC27 allele of msp-2 (91.1%), and 3D7 allele of msp-3 (53.5%) were the most prevalent among isolates from the 2013–2016 group. Compared with the 2006‒2007 group, polyclonal infection rates of msp-1 (from 76.7 to 29.1%, P < 0.01) and msp-2 (from 62.4 to 28.3%, P < 0.01) allelic types were significantly decreased in those from 2013‒2016 group. Similarly, the MOIs for both msp-1 and msp-2 were higher in P. falciparum isolates in the 2006–2007 group than those in 2013–2016 group (MOI = 3.11 vs 1.63 for msp-1; MOI = 2.75 vs 1.35 for msp-2). DNA sequencing analyses also revealed reduced numbers of distinct sequence variants in the three genes from 2006‒2007 to 2013‒2016: msp-1, from 32 to 23 (about 28% decline); msp-2 from 29 to 21 (about 28% decline), and msp-3 from 11 to 3 (about 72% decline). Conclusions The present data showed dramatic reduction in genetic diversity and MOI among Grande Comore P. falciparum populations over the course of the study, suggesting a trend of decreasing malaria transmission intensity and genetic diversity in Grande Comore Island. These data provide valuable information for surveillance of P. falciparum infection and for assessing the appropriateness of the current malarial control strategies in the endemic area.
Collapse
Affiliation(s)
- Bo Huang
- Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People's Republic of China.,Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Fei Tuo
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Yuan Liang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Wanting Wu
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Guangchao Wu
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Shiguang Huang
- School of Stomatology, Jinan University, Guangzhou, 510632, Guangdong, People's Republic of China
| | - Qirun Zhong
- Artepharm, Co., Ltd, Guangzhou, 510405, Guangdong, People's Republic of China
| | - Xin-Zhuan Su
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Hongying Zhang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Mingqiang Li
- Artepharm, Co., Ltd, Guangzhou, 510405, Guangdong, People's Republic of China
| | - Affane Bacar
- National Malaria Control Programme, BP 500, Moroni, Comoros
| | | | | | - Qi Wang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Zhaoli Yang
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Shaoqin Zheng
- Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China
| | - Qin Xu
- Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People's Republic of China
| | - Jianping Song
- Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People's Republic of China. .,Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China.
| | - Changsheng Deng
- Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, People's Republic of China. .,Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, 510445, Guangdong, People's Republic of China.
| |
Collapse
|
7
|
Niare S, Almeras L, Tandina F, Yssouf A, Bacar A, Toilibou A, Doumbo O, Raoult D, Parola P. MALDI-TOF MS identification of Anopheles gambiae Giles blood meal crushed on Whatman filter papers. PLoS One 2017; 12:e0183238. [PMID: 28817629 PMCID: PMC5560667 DOI: 10.1371/journal.pone.0183238] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 08/01/2017] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Identification of the source of mosquito blood meals is an important component for disease control and surveillance. Recently, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) profiling has emerged as an effective tool for mosquito blood meal identification, using the abdomens of freshly engorged mosquitoes. In the field, mosquito abdomens are crushed on Whatman filter papers to determine the host feeding patterns by identifying the origin of their blood meals. The aim of this study was to test whether crushing engorged mosquito abdomens on Whatman filter papers was compatible with MALDI-TOF MS for mosquito blood meal identification. Both laboratory reared and field collected mosquitoes were tested. MATERIAL AND METHODS Sixty Anopheles gambiae Giles were experimentally engorged on the blood of six distinct vertebrate hosts (human, sheep, rabbit, dog, chicken and rat). The engorged mosquito abdomens were crushed on Whatman filter papers for MALDI-TOF MS analysis. 150 Whatman filter papers, with mosquitoes engorged on cow and goat blood, were preserved. A total of 77 engorged mosquito abdomens collected in the Comoros Islands and crushed on Whatman filter papers were tested with MALDI-TOF MS. RESULTS The MS profiles generated from mosquito engorged abdomens crushed on Whatman filter papers exhibited high reproducibility according to the original host blood. The blood meal host was correctly identified from mosquito abdomens crushed on Whatman filter papers by MALDI-TOF MS. The MS spectra obtained after storage were stable regardless of the room temperature and whether or not they were frozen. The MS profiles were reproducible for up to three months. For the Comoros samples, 70/77 quality MS spectra were obtained and matched with human blood spectra. This was confirmed by molecular tools. CONCLUSION The results demonstrated that MALDI-TOF MS could identify mosquito blood meals from Whatman filter papers collected in the field during entomological surveys. The application of MALDI-TOF MS has proved to be rapid and successful, making it a new and efficient tool for mosquito-borne disease surveillance.
Collapse
Affiliation(s)
- Sirama Niare
- Aix Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, AP-HM, IHU Méditerranée Infection, Marseille, France
- Malaria Research and Training Center, DEAP/FMOS, UMI 3189, University of Science, Techniques and Technology, Bamako, Mali
| | - Lionel Almeras
- Aix Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, AP-HM, IHU Méditerranée Infection, Marseille, France
- Unité de Parasitologie et d’Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France
| | - Fatalmoudou Tandina
- Aix Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, AP-HM, IHU Méditerranée Infection, Marseille, France
- Malaria Research and Training Center, DEAP/FMOS, UMI 3189, University of Science, Techniques and Technology, Bamako, Mali
| | - Amina Yssouf
- Malaria Control Program, Moroni, Union of the Comoros
| | - Affane Bacar
- Malaria Control Program, Moroni, Union of the Comoros
| | - Ali Toilibou
- Malaria Control Program, Moroni, Union of the Comoros
| | - Ogobara Doumbo
- Malaria Research and Training Center, DEAP/FMOS, UMI 3189, University of Science, Techniques and Technology, Bamako, Mali
| | - Didier Raoult
- Aix Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, AP-HM, IHU Méditerranée Infection, Marseille, France
| | - Philippe Parola
- Aix Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198 (Dakar, Sénégal), Inserm 1095, AP-HM, IHU Méditerranée Infection, Marseille, France
- * E-mail:
| |
Collapse
|